Lung cancer "targeted and immunized"! First AXL kinase inhibitor bemcentinib in conjunction with Keytruda (Coreda) to demonstrate strong efficacy!

, 25 June 2020 /PRNewswire
/ -- BerGenBio is a biopharmaceutical company based in Norway dedicated to the development of new selective AXL kinase inhibitorsRecently, the company released positive data from Stage II (BGBC008) Stage 1 queue BThe team is evaluating AXL kinase inhibitor bemcentinib in conjunction with The meshadon anti-PD-1 therapy Keytruda (Corrida, generic name: pembrozumab, Pabolizumab), for the treatment of patients with non-small cell lung cancer (NSCLC) who have previously received immunocheckpoint inhibitors (including anti-PD-1 or anti-PD-L1 therapy) that have confirmed progression of the diseaseThe second phase of the study is recruiting patients(
full data details from the BGBC008 study:Virtual European Biotech Investor Day Solebury 25 June 2020)January, the company announced that the first phase of the pilot queue had reached the primary endpoint of the Total Mitigation Rate (ORR) and reached the criteria for extending the queue to Phase II (B2)BGBC008 (NCT03184571) is sponsored by BerGenBio in partnership with Mercado, who continues to provide Keytruda for research under an agreement signed in March 2017The study consisted of three queues that were being evaluated for the efficacy and safety of bemcentinib in conjunction with Keytruda's treatment of refractive NSCLCQueue A (completed group, patients are difficult to treat with first-line chemotherapy), Queue B (second-line patients in group: patients who have been treated with a single drug checkpoint inhibitor in first-line treatment), queue C (patients in group second line: patients who have received checkpoint inhibitors and chemotherapy combination in first-line treatment)the results of Queue B in this report are as follows: The first phase of Queue B consists of 12 patients who can evaluate compound AXL (cAXL), a biomarkerdeveloped by BerGenBio for a proprietary AXL immunohiscita chemicalOf the 12 patients, 7 were cAXL positive, of which 6 reported clinical benefits, including 1 partial remission (PR) and 1 PRi (unconfirmed partial remission);published in January this year a queue (Phase 1, Phase 2, n, 50% of patients are cAXL positive) data show: (1) cAXL-positive patients with a total remission rate (ORR) is 5 times that of cAXL-negative ;( patients; the report updated the total lifetime (OS) data for queue A, including a 12-month OS rate of 79% reported by cAXL-positive patients, a median OS (mOS) rate of 17.3 months (data continues to mature); (click on the image to see the larger picture) Richard Godfrey, chief executive of BerGenBio, said: "These interim clinical and transformational data further increase the confidence that patients benefit from the use of bemcentinib selective suppression AXL: cAXL-positive patients who relapse during immunotherapy can reverse resistance to immunocheckpoint inhibitors This would be an ideal alternative to standard treatment for second-line chemotherapy The latest data from Extended B2 Queues and Queue C will be available by the end of 2020 "
AXL kinase is a cell membrane receptor and an important medium for the inherent biological mechanisms of a variety of diseases In cancer, AXL inhibits the body's immune response to tumor and in many ways leads to cancer treatment failure In most cancers, the expression of AXL defines a subgroup with a very poor prognosis As a result, AXL inhibitors have potentially high value in the centerofing for cancer combination therapy, promising to meet a large number of unmet medical needs and multiple high-value market opportunities In addition, studies have shown that AXL mediates a variety of other invasive diseases bemcentinib is a pioneering (first-in-class), potent, oral, highly selective AXL inhibitor that targets and binds to the Intracellular catalytic kinase domain of AXL receptor tyrosine kinase
and inhibits its activity The enhancement of AXL function is related to the of tumor resistance and the key mechanisms of immune escape in tumors, leading to invasive metastatic cancer currently, BerGenBio is conducting an extensive Phase II clinical development program to assess the potential of bemcentinib as a monotherapy that combines current and emerging therapies (including immunotherapy, targeted therapy, chemotherapy) to treat a wide range of solid and blood tumor , including non-small cell lung cancer (NSCLC), melanoma
, acute myelin leukemia leukemia (AML) (BioValleyBioon.com) original source: BerGen Bio Announcs Positive Interim Clinical and Translational Data from Phase II of Bemcentinib in Combination with Keytruda? in Checkpoint Refract NSCLC Patients .